Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan | Zendy

Laura R. Harskamp | Zendy; Ron T. Gansevoort | Zendy; Wendy E. Boertien | Zendy; Wim van Oeveren | Zendy; Gerwin E. Engels | Zendy; Harry van Goor | Zendy; Esther Meijer | Zendy

Open Access

Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan

Author(s) -

Laura R. Harskamp,

Ron T. Gansevoort,

Wendy E. Boertien,

Wim van Oeveren,

Gerwin E. Engels,

Harry van Goor,

Esther Meijer

Publication year - 2015

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.09941014

Subject(s) - medicine , tolvaptan , autosomal dominant polycystic kidney disease , kidney , excretion , urinary system , receptor , endocrinology , urology , renal function , hyponatremia

Recent animal experiments suggest that dysregulation of the EGF receptor pathway plays a role in the pathophysiology of autosomal dominant polycystic kidney disease (ADPKD). Research on EGF receptor ligands in humans with ADPKD is lacking. EGF receptor ligands were measured in patients with ADPKD at baseline and after treatment with a vasopressin V2 receptor antagonist (V2RA) because this information might provide a rationale for future V2RA combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research